More about Concord Biotech Limited
Fundamentals for Concord Biotech Limited
Regulatory Filings for Concord Biotech Limited
Why Oman Is Now India's Most Strategic Trade Partner
Infrastructure Bet Fuels Cement Surge
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
Technicals for Concord Biotech Limited
Price Summary
Concord Biotech Limited's stock slumped -2.32% today, marking a lacklustre performance in the market.Concord Biotech Limited's stock started the year at 1230.0, climbed to a high of 1273.0, fell to 1189.0, and closed -2.32% lower at 1201.5, with 6052710 shares traded on 2026-06-03.
The stock's highest price in the past 52 weeks is 2130.4, while its lowest price during the same period is 1014.8.
Technicals
Support and Resistance: With the current price at 1201.5, support is found at 1109.0 and resistance at 1340.8. These levels indicate where buyers might step in at 1109.0, while sellers could limit gains at 1340.8, defining a trading boundary for Concord Biotech Limited.Aroon: The bullish trend indicated by Aroon persists, with Aroon Up holding steady at the 100 level. This shows strong market momentum, but further exploration using additional indicators is necessary to confirm the trend's strength and future potential.
Bol. Bands: The current price crossing below the upper Bollinger Band indicates a possible downward shift for CONCORDBIO. This signal might suggest that the asset is losing bullish momentum and could be preparing for a decline. Traders often view this as an early warning of an overbought condition, where the price correction is likely, making it a crucial point for evaluating potential short positions.
Parabolic SAR: The PSAR continues to be bullish for CONCORDBIO, setting a strong support level that could sustain the ongoing upward trend. This level of support indicates that the market is likely to continue its positive trajectory, offering a base for continued bullish movement.
Stochastic: The STOCHASTIC is currently in a neutral position for Concord Biotech Limited, offering no clear guidance on whether the market is likely to move up or down. This neutral stance suggests that further observation may be necessary before a trend becomes apparent.
Tripple Moving Agerage: The Tripple MOVING AVG is in a neutral stance for CONCORDBIO, not indicating a clear upward or downward trend. This suggests a period of market indecision, where neither bulls nor bears have the upper hand.
To properly assess the technical data of a company, it's important to first look at its fundamentals, such as its earnings, growth potential, and management effectiveness. Equally, understanding the industry trends, competition, and external economic factors that influence the company is vital. This holistic view helps draw meaningful conclusions about the company's technical performance, allowing investors to better gauge its stock price behavior, volatility, and market trends.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
How Independent Directors Failed Rs 2,500 Crore in Value